Study # ARTEMIDE-02/D702BC00001

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

Study Status:

Enrolling

Treatment Agent:

Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel

Description

Short Title: ARTEMIDE-02

The purpose of the study is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line (1L) treatment for patients with squamous metastatic non-small cell lung cancer (mNSCLC) whose tumors express PD-L1 (tumor cells (TC) ≥ 1%).

Resources and Links

National Clinical Trial Identified Number: NCT06692738

Information and next steps

Disease:

  • Non-Small Lung Disease

Study Phase:

III

Physician Name:

Department:

Ask a Question